[1]
|
American Diabetes Association, “Standards of Medical Care in Diabetes—2010,” Diabetes Care, Vol. 33, Suppl. 1, 2010, pp. S11-S61. doi:10.2337/dc10-S011
|
[2]
|
Z. H. Israili, “Advances in the Treatment of Type 2 Diabetes Mellitus,” American Journal of Therapeutics, Vol. 18, No. 2, 2011, pp. 117-152.
doi:10.1097/MJT.0b013e3181afbf51
|
[3]
|
M. J. Fowler, “Microvascular and Macrovascular Complications of Diabetes,” Clinical Diabetes, Vol. 26, No. 2, 2008, pp. 77-82.
|
[4]
|
D. M. Nathan, J. B. Buse, M. B. Davidson, et al., “American Diabetes Association; European Association for the Study of Diabetes. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, Vol. 32, No. 1, 2009, pp. 193-203.
doi:10.2337/dc08-9025
|
[5]
|
L. Y. Ngo, et al., “18th Report of the Malaysian Dialysis and Transplant Registry All Renal Replacement Therapy in Malaysia,” The National Renal Registry, Kuala Lumpur, 2010, pp. 1-3.
|
[6]
|
K. Shrishrimal, P. Hart and F. Michota, “Managing Diabetes in Hemodialysis Patients: Observations and Recommendations,” Cleveland Clinic Journal of Medicine, Vol. 76, No. 11, 2009, pp. 649-655.
doi:10.3949/ccjm.76a.09054
|
[7]
|
T. Oomichi, M. Emoto, T. Tabata, T. Morioka, Y. Tsujimoto, H. Tahara, T. Shoji and Y. Nishizawa, “Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis: A 7-Year Observational Study,” Diabetes Care, Vol. 29, No. 29, 2006, pp. 14961500. doi:10.2337/dc05-1887
|
[8]
|
M. E. Williams, E. Lacson Jr., M. Teng, N. Ofsthun and J. M. Lazarus, “Hemodialyzed Type I and Type II Diabetic Patients in the US: Characteristics, Glycemic Control, and Survival,” Kidney International, Vol. 70, No. 8, 2006, pp. 1503-1509. doi:10.1038/sj.ki.5001789
|
[9]
|
KDOQI, “KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease,” American Journal of Kidney Diseases, Vol. 49, No. 2, 2007, pp. S12-S154.
doi:10.1053/j.ajkd.2006.12.005
|
[10]
|
J. F. Yale, “Oral Antihyperglycemic Agents and Renal Disease: New Agents, New Concepts,” Journal of the American Society of Nephrology, Vol. 16, Suppl. 1, 2005, pp. S7-S10. doi:10.1681/ASN.2004110974
|
[11]
|
N. D. Lubowsky, R. Siegel and A. G. Pittas, “Management of Glycemia in Patients with Diabetes Mellitus and CKD,” American Journal of Kidney Diseases, Vol. 50, No. 5, 2007, pp. 865-879. doi:10.1053/j.ajkd.2007.08.012
|
[12]
|
K. Rave, T. Heise, A. Pfutzner, L. Heinemann and P. T. Sawicki, “Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients,” Diabetes Care, Vol. 24, No. 5, 2001, pp. 886-890. doi:10.2337/diacare.24.5.886
|
[13]
|
M. Stumvoll, “Glucose Production by the Human Kidney—Its Importance Has Been Underestimated,” Nephrology Dialysis Transplantation, Vol. 13, No. 12, 1998, pp. 2996-2999. doi:10.1093/ndt/13.12.2996
|
[14]
|
D. J. Drucker and M. A. Nauck, “GLP-1R Agonists (Incretin Mimetics) and DPP-4 Inhibitors (Incretin Enhancers) for the Treatment of Type 2 Diabetes,” Lancet, Vol. 368, No. 9548, 2006, pp. 1696-1705.
doi:10.1016/S0140-6736(06)69705-5
|
[15]
|
A. A. Tahrani, M. K. Piya and A. H. Barnett, “Saxagliptin: A New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus,” Advances in Therapy, Vol. 26, No. 3, 2009, pp. 249-262. doi:10.1007/s12325-009-0014-9
|
[16]
|
D. J. Drucker, “The Role of Gut Hormones in Glucose Homeostasis,” Journal of Clinical Investigation, Vol. 117, No. 1, 2007, pp. 24-32. doi:10.1172/JCI30076
|
[17]
|
A. Barnett, “DPP-4 Inhibitors and Their Potential Role in the Management of Type 2 Diabetes,” International Journal of Clinical Practice, Vol. 60, No. 11, 2006, pp. 14541470. doi:10.1111/j.1742-1241.2006.01178.x
|
[18]
|
J. Rosenstock, C. Aguilar-Salinas and E. Klein, “CV181011 Study Investigators. Effect of Saxagliptin Monotherapy in Treatment-Naive Patients with Type 2 Diabetes,” Current Medical Research and Opinion, Vol. 25, No. 10, 2009, pp. 2401-2411. doi:10.1185/03007990903178735
|
[19]
|
B. J. Goldstein, M. N. Feinglos, J. K. Lunceford, J. Johnson and D. E. Williams-Herman, “Effect of Initial Combination Therapy with Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients with Type 2 Diabetes,” Diabetes Care, Vol. 30, No. 8, 2007, pp. 1979-1987. doi:10.2337/dc07-0627
|
[20]
|
American Diabetes Association Workgroup on Hypoglycemia, “Defining and Reporting Hypo-glycemia in Diabetes,” Diabetes Care, Vol. 28, No. 5, 2005, pp. 1245-1249.
doi:10.2337/diacare.28.5.1245
|
[21]
|
Onglyza (Saxagliptin) Full Prescribing Information.
http://packageinserts.bms.com/pi/pi_onglyza.pdf
|
[22]
|
D. Boulton, A. Tang, C. Patel, L. Li, X. H. Xu, E. Frevert and D. Kornhauser, “Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin in Subjects with Renal Impairment,” Endocrine Abstracts, Vol. 20, 2009, p. 357.
|
[23]
|
M. S. Joy, W. T. Cefali, S. L. Hogan and P. H. Nachman, “Long-Term Glycemic Control Measurements in Diabetic Patients Receiving Hemodialysis,” American Journal of Kidney Diseases, Vol. 39, No. 2, 2002, pp. 297-307.
doi:10.1053/ajkd.2002.30549
|
[24]
|
A. H. Barnett, B. Charbonnel, M. Donovan and D. Fleming, “Effect of Saxagliptin as Add-On Therapy in Patients with Poorly Controlled Type 2 Diabetes on Insulin Alone or Insulin Combined with Metformin,” Current Medical Research & Opinion, Vol. 28, No. 4, 2012, pp. 1-12.
doi:10.1185/03007995.2012.665046
|
[25]
|
M. Nowicki, I. Rychlik, H. Haller, M. L. Warren, L. Suchower and I. G. Nilsson, “Saxagliptin Improves Glycemic Control and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus (T2DM) and Renal Impairment Compared with Placebo,” Diabetes, Obesity and Metabolism, Vol. 13, No. 6, 2011, pp. 523-532.
doi:10.1111/j.1463-1326.2011.01382.x
|
[26]
|
E. Lamb, T. R. Venton, W. R. Cattell and A. Dawnay, “Serum Glycated Albumin and Fructosamine in Renal Dialysis Patients,” Nephron, Vol. 64, No. 1, 1993, pp. 8288. doi:10.1159/000187283
|
[27]
|
M. Inaba, S. Okuno, Y. Kumeda, et al., “Osaka CKD Expert Research Group. Glycated Albumin Is a Better Glycemic Indicator than Glycated Hemoglobin Values in Hemodialysis Patients with Diabetes: Effect of Anemia and Erythropoietin Injection,” Journal of the American Society of Nephrology, Vol. 18, No. 3, 2007, pp. 896-903. doi:10.1681/ASN.2006070772
|
[28]
|
C. Constanti, J. M. Simo, J. Joven and J. Camps, “Serum Fructosamine Concentration in Patients with Nephrotic Syndrome and with Cirrhosis of the Liver: The Influence of Hypoalbuminaemia and Hypergammaglobulinaemia,” Annals of Clinical Biochemistry, Vol. 29, No. 4, 1992, pp. 437-442.
|
[29]
|
H. C. Ford, W. C. Lim and M. J. Crooke, “Hemoglobin A1 and Serum Fructosamine Levels in Hyperthyroidism,” Clinica Chimica Acta, Vol. 166, No. 2-3, 1987, pp. 317321. doi:10.1016/0009-8981(87)90435-9
|
[30]
|
M. Jadzinsky, A. Pfützner and E. Paz-Pacheco, “CV181039 Investigators. Saxagliptin Given in Combination with Metformin as Initial Therapy Improves Glycemic Control in Patients with Type 2 Diabetes Compared with Either Monotherapy: A Randomized Controlled Trial,” Journal of Diabetes, Obesity and Metabolism, Vol. 11, No. 6, 2009, pp. 611-622.
doi:10.1111/j.1463-1326.2009.01056.x
|
[31]
|
R. A. De Fronzo, M. Hissa, A. J. Garber, et al., “Saxagliptin 014 Study Group. The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients with Inadequately Controlled Type 2 Diabetes on Metformin Alone,” Diabetes Care, Vol. 32, No. 9, 2009, pp. 1649-1655. doi:10.2337/dc08-1984
|
[32]
|
A. R. Chacra, G. H. Tan, A. Apanovitch, S. Ravichandran, J. List and R. Chen, “Saxagliptin Added to a Submaximal Dose of Sulphonylurea Improves Glycaemic Control Compared with Uptitration of Sulphonylurea in Patients with Type 2 Diabetes: A Randomised Controlled Trial,” International Journal of Clinical Practice, Vol. 63, No. 9, 2009, pp. 1395-1406.
doi:10.1111/j.1742-1241.2009.02143.x
|
[33]
|
P. Hollander, J. Li, E. Allen and R. Chen, “CV181-013 Investigators. Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone,” The Journal of Clinical Endocrinology & Metabolism, Vol. 94, No. 12, 2009, pp. 4810-4819.
doi:10.1210/jc.2009-0550
|